{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:23:50Z","timestamp":1788236630124,"version":"build-2803163510"},"reference-count":9,"publisher":"Jaypee Brothers Medical Publishing","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.59556\/japi.74.1624","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:10:16Z","timestamp":1788235816000},"page":"13-16","source":"Crossref","is-referenced-by-count":0,"title":["Real-world Outcomes of Neoadjuvant Dual HER2 Blockade with TCHP in Early and Locally Advanced HER2-Enriched Breast Cancer: Experience from a South Indian Tertiary Oncology Center"],"prefix":"10.59556","volume":"74","author":[{"given":"Sanjana Reddy","family":"Potu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishesh","family":"Gumdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Koppaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hema Sireesha","family":"Natti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramya","family":"M","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudra Sanjeev","family":"Rudra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeena Moulasa","family":"Jaffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2914","reference":[{"issue":"(6):","key":"key20260901041011_B1","doi-asserted-by":"crossref","first-page":"791\u2013","DOI":"10.1016\/S1470-2045(16)00163-7","article-title":"5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.","volume":"17","author":"Gianni","year":"2016;","journal-title":"Lancet Oncol"},{"issue":"(9):","key":"key20260901041011_B2","doi-asserted-by":"crossref","first-page":"2278\u2013","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).","volume":"24","author":"Schneeweiss","year":"2013;","journal-title":"Ann Oncol"},{"issue":"(3):","key":"key20260901041011_B3","doi-asserted-by":"crossref","first-page":"646\u2013","DOI":"10.1093\/annonc\/mdx773","article-title":"Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study.","volume":"29","author":"Swain","year":"2018;","journal-title":"Ann Oncol"},{"issue":"(5):","key":"key20260901041011_B4","doi-asserted-by":"crossref","first-page":"321\u2013","DOI":"10.1093\/jnci\/djs528","article-title":"Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy.","volume":"105","author":"Marinovich","year":"2013;","journal-title":"J Natl Cancer Inst"},{"issue":"(9938):","key":"key20260901041011_B5","doi-asserted-by":"crossref","first-page":"164\u2013","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.","volume":"384","author":"Cortazar","year":"2014;","journal-title":"Lancet"},{"issue":"(17):","key":"key20260901041011_B6","doi-asserted-by":"crossref","first-page":"3608\u2013","DOI":"10.1200\/JCO.2004.01.175","article-title":"CNS metastases in breast cancer.","volume":"22","author":"Lin","year":"2004;","journal-title":"J Clin Oncol"},{"issue":"(7):","key":"key20260901041011_B7","doi-asserted-by":"crossref","first-page":"617\u2013","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer.","volume":"380","author":"von Minckwitz","year":"2019;","journal-title":"N Engl J Med"},{"issue":"(3):","key":"key20260901041011_B8","first-page":"719\u2013","article-title":"Real-world clinical outcomes of neoadjuvant pertuzumab-containing therapy in HER2-positive breast cancer patients.","volume":"53","author":"Ahn","year":"2021;","journal-title":"Cancer Res Treat"},{"issue":"(3):","key":"key20260901041011_B9","first-page":"647\u2013","article-title":"Real-world effectiveness of neoadjuvant dual HER2 blockade in early HER2-positive breast cancer.","volume":"181","author":"Schneeweiss","year":"2020;","journal-title":"Breast Cancer Res Treat"}],"container-title":["Journal of The Association of Physicians of India"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:10:18Z","timestamp":1788235818000},"score":1,"resource":{"primary":{"URL":"https:\/\/japi.org\/article\/japi-74-8-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":9,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.59556\/japi.74.1624"],"URL":"https:\/\/doi.org\/10.59556\/japi.74.1624","relation":{},"ISSN":["0004-5772"],"issn-type":[{"value":"0004-5772","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]}}}